Search

Three-dimensional (3D) molecular generation models employ deep neural networks to simultaneously generate both topological representation and molecular conformations. Due to their advantages in utilizing the structural and interaction information on targets, as well as their reduced reliance on existing bioactivity data, these models have attracted widespread attention. However, limited training and testing data sets and the unexpected biases inherent in single evaluation metrics pose a significant challenge in comparing these models in practical settings. In this work, we proposed Durian, an evaluation framework for structure-based 3D molecular generation that incorporates protein–ligand data with experimental affinity and a comprehensive array of physicochemical and geometric metrics. The benchmark tasks encompass assessing the capability of models to reproduce the property distribution of training sets, generate molecules with rational distributions of drug-related properties, and exhibit potential high affinity toward given targets. Binding affinities were evaluated using three independent docking methods (QuickVina2, Surflex and Gnina) with both “Dock” and “Score” modes to reduce false positives arising from conformational searches or scoring functions. Specifically, we applied Durian to six 3D molecular generation methods: LiGAN, Pocket2Mol, DiffSBDD, SBDD, GraphBP, and SurfGen. While most methods demonstrated the ability to generate drug-like small molecules with reasonable physicochemical properties, they exhibited varying degrees of limitations in balancing novelty, structural rationality, and synthetic accessibility, thereby constraining their practical applications in drug discovery. Based on a total of 17 metrics, Durian highlights the importance of multiobjective optimization in 3D molecular generation methods. For instance, SurfGen and SBDD showed relatively comprehensive performance but could benefit from further improvements in molecular conformational rationality. Our evaluation framework is expected to provide meaningful guidance for the selection, optimization, and application of 3D generative models in practical drug design tasks.

Ab initio total energy calculations were performed to study the adsorption of atomic hydrogen on the polar surface of Zn–ZnO(0001) for different degrees of surface coverage. The most stable configuration was calculated as a function of the distance between H and the surface. The present results show that the manifest ferromagnetism depends on purely surface interactions. It involves charge transfer from the H-1s level to the Zn-4s level, leading to a magnetic moment of 1.0 μBfor full H surface coverage in the supercell. The magnetic interaction between H atoms is ferromagnetic. In addition, for a fully hydrogenated ZnO monolayer with zinc vacancies (VZn) or hydrogen-passivated zinc vacancies (VZn–H), a transition from a nonmagnetic semiconductor to a magnetic half-metal semiconductor has been achieved. Both configurations exhibit a surface magnetic moment of 2.0 μB, which is twice that obtained for the case without the vacancy. These theoretical calculations agree with our previously published experimental results, where it was observed that hydrogen is incorporated into the ZnO structure and acts as a surface donor.

Enhanced sampling simulations make the computational study of rare events feasible. A large family of such methods crucially depends on the definition of some collective variables (CVs) that could provide a low-dimensional representation of the relevant physics of the process. Recently, many methods have been proposed to semiautomatize the CV design by using machine learning tools to learn the variables directly from the simulation data. However, most methods are based on feedforward neural networks and require some user-defined physical descriptors. Here, we propose bypassing this step using a graph neural network to directly use the atomic coordinates as input for the CV model. This way, we achieve a fully automatic approach to CV determination that provides variables invariant under the relevant symmetries, especially the permutational one. Furthermore, we provide different analysis tools to favor the physical interpretation of the final CV. We prove the robustness of our approach using different methods from the literature for the optimization of the CV, and we prove its efficacy on several systems, including a small peptide, an ion dissociation in explicit solvent, and a simple chemical reaction.

Background: Pain fluctuations are a characteristic phenomenon in advanced Parkinson’s disease (PD), but their temporal association with motor and non-motor symptom (NMS) fluctuations remains largely enigmatic. Moreover, data on their importance for disease severity perception and health-related quality-of-life (hr-QoL) is limited.Objective: To dissect pain fluctuations with respect to pain type and frequency patterns, and their association with motor and non-motor fluctuations.Methods: Prospective observational cohort study in advanced PD assessing symptom fluctuations by simultaneous hourly ratings using the PD Home diary (Off, On, Dyskinetic state), a pain diary (assessing 9 pain types) and a non-motor diary (10 key NMS) based on validated instruments.Results: Forty-seven out of 55 eligible participants with fluctuating PD (51% men, median age 65, median disease duration 10 years) had sufficient datasets (>95% of hours) from 2 consecutive days. Pain was reported in 35% of waking hours with clear circadian rhythm peaking in early morning Off periods and clustering during motor Off state (49% of Off state hours with pain). Main NMS co-fluctuating with pain were “Fatigue” and “Inner Restlessness”. Simultaneous assessment of global disease severity by participants revealed that pain was associated with worse disease severity only in motor On and Dyskinetic state but not in Off state, which translated into significant correlations of daily pain times with hr-QoL only during motor On and Dyskinetic state.Conclusions: Aside from treating motor Off periods, specific recognition of pain particularly during motor On and Dyskinetic state comprises an important aspect for disease management in advanced PD.

Pain fluctuations are a characteristic phenomenon in advanced Parkinson’s disease (PD), but their temporal association with motor and non-motor symptom (NMS) fluctuations remains largely enigmatic. Moreover, data on their importance for disease severity perception and health-related quality-of-life (hr-QoL) is limited. To dissect pain fluctuations with respect to pain type and frequency patterns, and their association with motor and non-motor fluctuations. Prospective observational cohort study in advanced PD assessing symptom fluctuations by simultaneous hourly ratings using the PD Home diary (Off, On, Dyskinetic state), a pain diary (assessing 9 pain types) and a non-motor diary (10 key NMS) based on validated instruments. Forty-seven out of 55 eligible participants with fluctuating PD (51% men, median age 65, median disease duration 10 years) had sufficient datasets (>95% of hours) from 2 consecutive days. Pain was reported in 35% of waking hours with clear circadian rhythm peaking in early morning Off periods and clustering during motor Off state (49% of Off state hours with pain). Main NMS co-fluctuating with pain were “Fatigue” and “Inner Restlessness”. Simultaneous assessment of global disease severity by participants revealed that pain was associated with worse disease severity only in motor On and Dyskinetic state but not in Off state, which translated into significant correlations of daily pain times with hr-QoL only during motor On and Dyskinetic state. Aside from treating motor Off periods, specific recognition of pain particularly during motor On and Dyskinetic state comprises an important aspect for disease management in advanced PD. Oscillations of the frequency and severity of pain over the day (also called pain fluctuations) are common in advanced Parkinson’s disease (PD). However, their relationship with oscillations of motor and other non-motor symptoms remains unclear. Moreover, only very little data exists on how pain impacts disease severity perception and quality of life for the patients. The present study thus aimed to better understand pain fluctuations and their association with motor and non-motor symptoms in advanced PD. We conducted a prospective observational cohort study in advanced PD patients. Participants rated their symptoms hourly on two consecutive days using three diaries: the PD Home diary (for motor fluctuations), a pain diary (assessing several pain types), and a non-motor diary covering 10 key non-motor symptoms. Pain occurred during 35% of waking hours with a clear circadian rhythm peaking in the early morning and clustering during motor “Off” states as characterized by pronounced motor symptoms. The main non-motor symptoms associated with pain were “Fatigue” and “Inner Restlessness.” Interestingly, pain severity correlated with health-related quality of life only during motor “On” state (defined as a state with good mobility and motor function) and “Dyskinetic” state characterized by the occurrence of involuntary movements, but not during motor “Off” periods. In conclusion, in managing advanced PD, recognizing pain during motor “On” and Dyskinetic states is crucial beyond just addressing motor “Off” periods. This understanding can significantly impact disease management and improve patients’ quality of life.

Artificial intelligence (AI)-aided drug design has demonstrated unprecedented effects on modern drug discovery, but there is still an urgent need for user-friendly interfaces that bridge the gap between these sophisticated tools and scientists, particularly those who are less computer savvy. Herein, we present DrugFlow, an AI-driven one-stop platform that offers a clean, convenient, and cloud-based interface to streamline early drug discovery workflows. By seamlessly integrating a range of innovative AI algorithms, covering molecular docking, quantitative structure–activity relationship modeling, molecular generation, ADMET (absorption, distribution, metabolism, excretion and toxicity) prediction, and virtual screening, DrugFlow can offer effective AI solutions for almost all crucial stages in early drug discovery, including hit identification and hit/lead optimization. We hope that the platform can provide sufficiently valuable guidance to aid real-word drug design and discovery. The platform is available at https://drugflow.com.

Background: Non-motor symptoms (NMS) reduce quality of life in Parkinson’s disease (PD) patients, who experience three times more NMS than individuals without PD. While there are international and national NMS treatment guidelines, their implication in clinical practice remains unclear.Objective: This study aimed to investigate the adherence to pharmacological NMS treatment guidelines in patients with mild to moderately severe PD.Methods: 220 PD patients with ≥1 NMS based on the Non-Motor Symptom Questionnaire and a Hoehn and Yahr stage ≤4 were randomly selected from the Swedish Parkinson registry and screened for inclusion. NMS were evaluated using the International Parkinson and Movement Disorder Society–Non-Motor Rating Scale (MDS-NMS), Parkinson’s Disease Sleep Scale 2, Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Treatment was compared with Swedish national guidelines and international guidelines from the MDS Evidence-Based Medicine Committee.Results: Among 165 included patients, the median number of NMS was 14, and in median 7 symptoms were estimated to require treatment. The most common NMS requiring treatment were pain (69%) and urinary problems (56%). Treatment of depression and constipation demonstrated the highest adherence to guidelines (79% and 77%), while dysphagia and excessive daytime sleepiness exhibited the lowest adherence (0% and 4%). On average, only 32% of NMS were treated in accordance with guidelines.Conclusions: Adherence to pharmacological guidelines for NMS in patients with mild to severe PD was low. This study highlights the need for improved evaluation and treatment of NMS to enhance symptom management and quality of life among PD patients.

Smallpox was eradicated in 1980 but remains a biothreat due to the potential release of variola virus into the general population. Brincidofovir, the second medicine approved by the US Food and Drug Administration to treat smallpox, is metabolized by oxidative and hydrolytic pathways. The oxidative pathway is initiated by cytochrome P450 4F2 (CYP4F2), an enzyme lacking clinical probes for drug interaction studies. The aim of this work was to assess the impact of reduced activity CYP4F2 variants (rs2108622, C/T and T/T) on brincidofovir pharmacokinetics as a surrogate for drug inhibition. Genotyping was performed on blood from healthy participants receiving oral (n = 261) and intravenous (IV, n = 49) brincidofovir across 6 phase 1 trials. Plasma concentrations were measured by validated liquid chromatography tandem mass spectrometry methods. After oral administration, subjects with the lowest activity CYP4F2 genotype (T/T) had up to 36% higher AUCinfand 29% higher Cmaxwhile subjects with the moderate activity CYP4F2 genotype (C/T) had similar Cmaxand AUCinfcompared to those with the wild‐type genotype. Little to no increase in brincidofovir exposure parameters was observed following IV administration. Based on the lack of significant increases in brincidofovir plasma concentrations in subjects with low activity CYP4F2, a clinically meaningful drug–drug interaction is not expected with CYP4F2 inhibitor and brincidofovir coadministration.

Work-class ROVs are essential vehicles for subsea inspection, maintenance, and repair tasks. To improve ROV piloting skills, a virtual environment can be exploited to train pilots in underwater operations without the logistical and financial expenses of actual sea deployments. This paper presents a high-fidelity ROV simulator for pilot training, utilizing the Unity framework for photorealistic scene rendering. The simulator integrates with ROS for control tasks and is accessible via a WebSocket TCP/IP package, enabling remote user access. A practical application is demonstrated, where a simulated work-class ROV (Merlin ROV) engages with a visually rendered scene of a subsea installation in the North Sea. The simulation framework aims to bridge the gap between virtual training and real-world operations by providing realistic graphics and accurate control dynamics. This work highlights the potential of game engine-based simulators in advancing the capabilities and efficiency of ROV pilot training.

Background: Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a gradual deterioration in patients’ quality of life, despite optimal treatment, and both medical and societal needs increase, often with the assistance of paid and/or unpaid caregivers. Objective: We aimed to quantify the incremental economic burden of Parkinson’s disease by disease severity in a real-world setting across differing geographic regions. Methods: Demographics, clinical characteristics, health status, patient quality of life, caregiver burden, and healthcare resource utilization data were drawn from the Adelphi Parkinson’s Disease Specific Program™, conducted in the USA, five European countries, and Japan. Results: A total of 563 neurologists provided data for 5299 individuals with Parkinson’s disease; 61% were male, with a mean age of 64 years. Approximately 15% of individuals were deemed to have advanced disease, with significantly more comorbidities, and a poorer quality of life, than those with non-advanced disease. Overall, the mean annual healthcare resource utilization increased significantly with advancing disease, and resulted in a three-fold difference in the USA and Europe. The main drivers behind the high economic burden included hospitalizations, prescription medications, and indirect costs. Conclusions: People with Parkinson’s disease, and their caregivers, incur a higher economic burden as their disease progresses. Future interventions that can control symptoms or slow disease progression could reduce the burden on people with Parkinson’s disease and their caregivers, whilst also substantially impacting societal costs.

Non-motor symptoms (NMS) reduce quality of life in Parkinson’s disease (PD) patients, who experience three times more NMS than individuals without PD. While there are international and national NMS treatment guidelines, their implication in clinical practice remains unclear. This study aimed to investigate the adherence to pharmacological NMS treatment guidelines in patients with mild to moderately severe PD. 220 PD patients with ≥1 NMS based on the Non-Motor Symptom Questionnaire and a Hoehn and Yahr stage ≤4 were randomly selected from the Swedish Parkinson registry and screened for inclusion. NMS were evaluated using the International Parkinson and Movement Disorder Society–Non-Motor Rating Scale (MDS-NMS), Parkinson’s Disease Sleep Scale 2, Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Treatment was compared with Swedish national guidelines and international guidelines from the MDS Evidence-Based Medicine Committee. Among 165 included patients, the median number of NMS was 14, and in median 7 symptoms were estimated to require treatment. The most common NMS requiring treatment were pain (69%) and urinary problems (56%). Treatment of depression and constipation demonstrated the highest adherence to guidelines (79% and 77%), while dysphagia and excessive daytime sleepiness exhibited the lowest adherence (0% and 4%). On average, only 32% of NMS were treated in accordance with guidelines. Adherence to pharmacological guidelines for NMS in patients with mild to severe PD was low. This study highlights the need for improved evaluation and treatment of NMS to enhance symptom management and quality of life among PD patients.

The Shuttle has a hardware RAID controller and is capable of being configured with 4 TB, 6 TB, 8 TB and 12 TB drives, or with two 10 or 12 TB drives and two EV bays. Ultimately, choosing the right drive or drives comes down to understanding how the drive will fit into your workflow. Features In this guide, you'll find a list of the best storage drives on the market today, hand-picked by the Videomaker editors. In a case like this, the data may still be on the drives, but recovery might be difficult since many RAID controllers write data to drives differently. [Extracted from the article]

ObjectivesThe study aimed to compare the quality of life (QoL) among cancer-bereaved parents with a control group and explore how resilience and support from healthcare professionals associated with QoL of parents 2–8 years after the loss of a child to cancer.MethodsThis nationwide, cross-sectional survey was administered among parents (n=161) who lost their child to cancer between 2009 and 2014, compared with a matched control parent group (n=77). A study-specific questionnaire, Resilience Scale for Adults (six factors: ‘Perception of self’, ‘Planned future’, ‘Social competence’, ‘Structured style’, ‘Family cohesion’ and ‘Social resources’), and a single-item measure of parents’ QoL were included for the study.ResultsThere was a lower QoL in both bereaved parents (mean=5.1) compared with the control parents (mean=5.8) (p<0.001). Two resilience factors, ‘Perception of self’ (OR=1.8, p=0.004) and ‘Planned future’ (OR=2.05, p<0.001), and given sufficient information during the child’s last month (OR=2.63, p=0.003) were positively associated with long-term QoL in cancer-bereaved parents.ConclusionThe findings indicate lower QoL among both fathers and mothers 2–8 years after losing a child to cancer. The study also highlights the positive role of resilience and the importance of informational support on long-term QoL in cancer-bereaved parents. Bereavement support should be tailored for supporting individual needs.

In the Anthropocene, humans are drastically impacting the Earth system. Though the numbers are disputed, millions of climate refugees might soon appear worldwide due to, for example, rising sea levels. To better tackle these intertwined ecological and migrational crises, I expand on Seyla Benhabib’s theoretical legacy by discerning within it a multidimensional framework containing mutually intersecting moral, legal, and political dimensions. Within this framework, I argue, Benhabib approaches the issue of climate refugees from three different yet supplementary discourses. From her engagement with discourses on cosmopolitanism and global justice, she endorses reforming the Refugee Convention to include climate refugees. From her contribution to discourses on human rights and human dignity, Benhabib opens the door for a human right to the environment to better protect climate refugees. Against the backdrop of her longstanding work to reformulate a feminist and critical-theoretical discourse ethics, I argue, Benhabib puts forward an ecocentric planetary ethics that embraces climate refugees and the rest of nature. In all, I conclude that Benhabib’s legacy demonstrates the need for a multidimensional approach to climate refugees in times of ecocrisis.

ABSTRACTThis study investigated resilience patterns and predictors of these patterns (i.e. gender and migration background) among Swiss early adolescents in times of COVID-19. A total of 317 pupils participated at two time points. We conducted two separate latent class analyses and a latent transition analysis using mental health issues and protective factors as indicators. The results revealed three groups: resilient (high mental health issues, high protective factors), nonresilient (high mental health issues, low protective factors), and untroubled (low mental health issues, high protective factors). The resilient group was the most stable (91% stability), whereas the untroubled was the least stable (69% stability). Boys were more likely to be part of the untroubled group than the other groups at the second time point. Gender at the first time point and migration background at both time points were nonsignificant as predictors. Findings highlight the importance of group-specific research, health promotion, and interventions.

Abstract: The review presents the analysis of publications about the peculiarities of the manifestation of systemic lupus erythematosus (SLE) in individuals of older age groups. The probable reasons and mechanisms of the development of neurological manifestations of the disease are reflected in the work. The clinical pattern in elderly patients is described in detail and the peculiarities of immune indices are noted. This article considers different variants of nervous-system damage with SLE that differ in a wide spectrum of clinical manifestations. Neurobehavioral disorders with SLE are one of the least studied aspects and can be both a manifestation of the main disease (including those coinciding with the processes of immunoaging) and adverse events during the treatment. At the same time, knowledge of the peculiarities of neurological manifestations with SLE with its onset in late ontogenesis in comparison with the data of laboratory and instrumental methods of examination allow early diagnosis to be carried out and adequate therapy for elderly patients to be established in a timely manner.

Background: In advanced Parkinson’s disease (PD), dyskinesias and non-motor symptoms such as sleep dysfunction can significantly impair quality of life, and high-quality management is an unmet need.Objective: To analyze changes in dyskinesia and non-motor symptoms (including sleep) among studies with levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD.Methods: A comprehensive literature review identified relevant studies examining LCIG efficacy. Outcomes of interest were dyskinesia (UDysRS, UPDRS IV item 32), overall non-motor symptoms (NMSS), mentation/behavior/mood (UPDRS I), and sleep/daytime sleepiness (PDSS-2, ESS). The pooled mean (95% confidence interval) change from baseline per outcome was estimated for each 3-month interval with sufficient data (i.e., reported by≥3 studies) up to 24 months using a random-effects model.Results: Seventeen open-label studies evaluating 1243 patients with advanced PD were included. All outcomes of interest with sufficient data for meta-analysis showed statistically significant improvement within 6 months of starting LCIG. There were statistically significant improvements in dyskinesia duration as measured by UPDRS IV item 32 at 6 months (–1.10 [–1.69, –0.51] h/day) and 12 months (–1.35 [–2.07, –0.62] h/day). There were statistically and clinically significant improvements in non-motor symptoms as measured by NMSS scores at 3 months (–28.71 [–40.26, –17.15] points). Significant reduction of NMSS burden was maintained through 24 months (–17.61 [–21.52, –13.70] points). UPDRS I scores significantly improved at 3 months (–0.39 [–0.55, –0.22] points). Clinically significant improvements in PDSS-2 and ESS scores were observed at 6 and 12 months in individual studies.Conclusion: Patients with advanced PD receiving LCIG showed significant sustained improvements in the burden of dyskinesia and non-motor symptoms up to 24 months after initiation.

Immune checkpoint inhibitors (ICIs) have advanced the treatment of non-small cell lung cancer (NSCLC). This study evaluates the predictive value of CD8+T cell exhaustion in patients with lung adenocarcinoma treated with ICIs. By analyzing tumor samples from 166 patients through multiplex immunofluorescence, we quantify tumor-infiltrating lymphocytes (TILs) expressing exhaustion markers programmed cell death-1 (PD1), lymphocyte activation gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), and T cell immunoglobulin and mucin domain 3 (TIM3). Their co-expression is associated with ICI resistance, irrespective of programmed cell death ligand-1 (PD-L1) status.

Cognitive-behavioral therapy including exposure and response prevention is the first-line treatment of pediatric OCD showing response- and remission rates around 70% and 53%. Thus, there is room for improvements. Metacognitive therapy (MCT) for OCD might be cost-effective and focuses on modifying metacognitive beliefs about the significance and dangerousness of intrusive thoughts/feelings, and about the need to perform rituals. MCT is effective in adults but needs to be evaluated in youths. In the current study, eleven adolescents divided in three groups received eight MCT group sessions of 75 min duration (and two 60 min workshop for parents) delivered by an MCT-therapist and an assistant. The within-group effect size (hedges g) from pre-to post-treatment on the CY-BOCS was 1.90, and the response and remission rates were 82% and 55%, respectively. Effect sizes for secondary outcomes were also large. Therapist time (one certified MCT-therapist and a clinical psychology student working together) used per patient to achieve these results were 2.18 therapy sessions of 75-min duration in addition to 33 min therapist time per patient of workshops for the parents. Follow-up assessments were not available, and the results should be interpreted with caution. However, they are encouraging and suggest that MCT for pediatric OCD should be evaluated further.

An interaction of 1,5-diaryl-3-X-pent-4-yn-1-ones (where X stands for piperidin-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl) with arylhydrazines proceeds at room temperature and results in 3-aryl-5-arylethynyl-1-phenyl-4,5-dihydro-1H-pyrazoles with up to 57–73% yields. Under similar conditions, the cyclocondensation of conjugated 2,4,1-enynones with arylhydrazine proceeds only in the presence of cyclic amines. 1,5-Diaryl-3-X-pent-4-yn-1-ones are reported as synthetic equivalents of conjugated 2,4,1-enynones in reactions with arylhydrazines. On the basis of obtained data, there are highly efficient methods developed for the synthesis of 5-arylethynyl-substituted 4,5-dihydro-1H-pyrazoles, as well as for similarly structured 1H-pyrazoles prepared by oxidation in AcOH. Presented products possess quite marked fluorescent abilities. Emission maximum wavelengths are located at 453–465 and 363–400 nm, respectively; certain compounds show extremely large Stokes shifts that may reach 91,000 cm–1.

Features In this article, we'll highlight our picks for the best video editing laptops on the market today, then go over the main points a potential buyer will want to consider in choosing the right mobile workstation. Best portable laptop MSI Creator 15 Design specifically for creators, the MSI Creator 15 features a 2.3 GHz Intel Core i7-10875H eight-core processor, a 15.6" Full HD IPS Display and 512GB NVMe PCIe M.2 SSD. Best performance laptop HP Zbook Studio 15.6" G8 You would be hard-pressed to find a more powerful laptop than the HP Zbook Studio 15.6" G8 Mobile Workstation. [Extracted from the article]

This article from Videomaker provides a guide for building a custom PC for video editing. It highlights the best PC components currently on the market, including the best CPU, RAM, GPU, and system drive options. The article emphasizes the importance of considering factors such as performance, price, and compatibility when selecting these components. It also offers budget-friendly alternatives for each category. The article concludes by advising readers to build a system that meets their specific video editing needs without overspending on unnecessary features. [Extracted from the article]

This article provides a list of the best laptops for video editing in 2024. It highlights several options for different budgets and preferences. The Asus Vivobook Pro 15 OLED is recommended as the best budget laptop, offering a powerful processor and graphics at an affordable price. The MSI Creator M16 is suggested as the best portable laptop, with impressive processing power and a high-quality display. For Mac users on a budget, the Apple 14-inch MacBook Pro M2 is recommended, while the Apple 16-inch MacBook Pro M2 Max is suggested as the best Mac laptop overall. The HP ZBook Studio G9 is highlighted as the best performance laptop, and the MSI 15.6-inch Stealth 15 is recommended for editors who also enjoy gaming. The article also provides guidance on choosing the right laptop, including considerations such as operating system, screen size and resolution, battery life, connectivity, and portability. [Extracted from the article]

Abstract: This article is devoted to the life and work of the Russian–British scientist, Professor of the Imperial Military Medical Academy in St. Petersburg, and Head of the Oxford Gerontological Research Unit, Vladimir Georgievich Korenchevsky. The theory of endocrine aging and the concept of geroprotective hormone replacement therapy are among the scientific achievements of V.G. Korenchevsky. He inspired and organized congresses and societies of Russian academic organizations abroad, as well as inspiring and organizing the British Society for Research on Ageing and the International Association of Gerontology and Geriatrics.